Drugs for Cryoglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 29)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
rituximab |
Approved |
Phase 4,Phase 2,Phase 3 |
|
174722-31-7 |
10201696
|
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
Ig gamma-1 chain C region
|
Mabthera
MabThera
Rituxan
rituximab
|
|
2 |
|
Antirheumatic Agents |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
3 |
|
Ledipasvir |
Approved |
Phase 2, Phase 3 |
|
1256388-51-8 |
67505836
|
Synonyms:
methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate
|
|
|
4 |
|
Sofosbuvir |
Approved |
Phase 2, Phase 3 |
|
1190307-88-0 |
45375808
|
Synonyms:
S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate
|
|
|
5 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3,Phase 1 |
|
|
|
6 |
|
Antiviral Agents |
|
Phase 2, Phase 3,Phase 1 |
|
|
|
7 |
|
Ledipasvir, sofosbuvir drug combination |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4, 85898-30-2 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Interleukin-2 aldesleukin
|
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
|
|
9 |
|
Prednisone |
Approved, Vet_approved |
Phase 2 |
|
53-03-2 |
5865
|
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
Adasone
AI3-52939
Ancortone
Apo-prednisone
Apo-Prednisone
Betapar
Bicortone
Bio-0649
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
C07370
C21H26O5
Cartancyl
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
CPD001227202
Dacorten
Dacortin
DB00635
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
delta cortelan
Delta Cortelan
Delta E
Delta E.
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
Delta-cortelan
Delta-Cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Delta-cortisone
delta-Cortone
Deltacortone
Delta-cortone
Delta-dome
Delta-Dome
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Econosone
EINECS 200-160-3
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
|
HMS1568O15
HMS2090J13
Hostacortin
HSDB 3168
Incocortyl
In-Sone
Juvason
Kortancyl
Liquid Pred
Lisacort
LMST02030180
Lodotra
LS-1325
MEGxm0_000443
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI60_000008
NCI-C04897
Nisona
Nizon
Novoprednisone
NSC 10023
NSC10023
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
Panafcort
Panasol
Paracort
Parmenison
Pehacort
PRD
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone [INN:BAN]
Prednisone Intensol
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick_405
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
Servisone
SK-Prednisone
SMR000718760
SMR001227202
Sone
SPBio_002214
Sterapred
Supercortil
U 6020
Ultracorten
Ultracortene
UNII-VB0R961HZT
Winpred
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Wojtab
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
ZINC03875357
|
|
10 |
|
Lactitol |
Investigational |
Phase 1, Phase 2 |
|
585-86-4 |
3871
|
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
Floralac
|
|
|
11 |
|
Analgesics |
|
Phase 1, Phase 2 |
|
|
|
12 |
|
Analgesics, Non-Narcotic |
|
Phase 1, Phase 2 |
|
|
|
13 |
|
Interleukin-2 |
|
Phase 1, Phase 2 |
|
|
|
14 |
|
Peripheral Nervous System Agents |
|
Phase 1, Phase 2 |
|
|
|
15 |
|
s 1 (combination) |
|
Phase 1, Phase 2 |
|
|
|
Synonyms:
Gimeracil / oteracil / tegafur
|
|
|
16 |
|
Anti-HIV Agents |
|
Phase 1, Phase 2 |
|
|
|
17 |
|
Anti-Retroviral Agents |
|
Phase 1, Phase 2 |
|
|
|
18 |
|
Antibodies |
|
Phase 2 |
|
|
|
19 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
20 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
21 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
22 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
23 |
|
glucocorticoids |
|
Phase 2 |
|
|
|
24 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
25 |
|
Hormones |
|
Phase 2 |
|
|
|
26 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 2 |
|
|
|
27 |
|
Ribavirin |
Approved |
|
|
36791-04-5 |
37542
|
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
C-Virin
D00423
DB00811
DivK1c_000782
DRG-0028
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
Lopac0_001063
LS-1241
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
NSC163039
|
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
Ravanex
RBV
Rebetol
Rebetol (TN)
Rebetron
Rebretron
RG-964
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
RIBAV
ribavirin
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin [USAN:INN]
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirin-TP
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
RTC
RTCA
RTP
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
Spectrum_001826
SPECTRUM1503938
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
SR-01000076112-3
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
|
|
28 |
|
Liver Extracts |
|
|
|
|
|
29 |
|
interferons |
|
|
|
|
|
Interventional clinical trials:
(show all 19)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab |
Completed |
NCT00820469
|
Phase 4 |
Rituximab 375;rituximab 1000 |
2 |
Tolerance and Efficacy of Rituximab in Sjogren's Disease |
Completed |
NCT00740948
|
Phase 2, Phase 3 |
Rituximab (mabthera) Injection;Placebo: NaCl 0.9% or Glucose 5% |
3 |
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia |
Recruiting |
NCT02825212
|
Phase 2, Phase 3 |
Harvoni |
4 |
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata |
Unknown status |
NCT01840046
|
Phase 1, Phase 2 |
Interleukin-2 |
5 |
Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients |
Completed |
NCT00574652
|
Phase 1, Phase 2 |
Proleukin |
6 |
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis |
Completed |
NCT00029107
|
Phase 2 |
Rituximab |
7 |
Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis |
Active, not recruiting |
NCT02556866
|
Phase 2 |
rituximab;Prednisone;Placebo |
8 |
Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting |
Unknown status |
NCT01932021
|
|
|
9 |
Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia |
Completed |
NCT03342261
|
|
DAA treatment |
10 |
Characterization of Clonal B Cell Populations in HCV Infection |
Completed |
NCT00435201
|
|
|
11 |
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders |
Completed |
NCT00960713
|
|
Rituximab (MABTHERA® or RITUXAN®). |
12 |
Hepatitis C Virus and the Humoral Immune System |
Completed |
NCT00219999
|
|
|
13 |
Impact of Vasculitis on Employment and Income |
Completed |
NCT02476292
|
|
|
14 |
Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis |
Recruiting |
NCT02856243
|
|
new antiviral therapy |
15 |
Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment |
Recruiting |
NCT03042520
|
|
|
16 |
Journey of Patients With Vasculitis From First Symptom to Diagnosis |
Recruiting |
NCT03410290
|
|
|
17 |
Clinical Transcriptomics in Systemic Vasculitis (CUTIS) |
Recruiting |
NCT03004326
|
|
|
18 |
Vasculitis Pregnancy Registry |
Recruiting |
NCT02593565
|
|
|
19 |
Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy |
Not yet recruiting |
NCT03226717
|
|
Antiviral agents |
Inferred drug relations via
UMLS
69
/
NDF-RT
47
:
Cochrane evidence based reviews: cryoglobulinemia
|